Copyright
©The Author(s) 2025.
World J Clin Oncol. Feb 24, 2025; 16(2): 98079
Published online Feb 24, 2025. doi: 10.5306/wjco.v16.i2.98079
Published online Feb 24, 2025. doi: 10.5306/wjco.v16.i2.98079
Table 2 Summary of tumor response and survival outcomes according to Response Evaluation Criteria in Solid Tumors 1.0 Criteria, n (%)
| Outcomes | Combination group (n = 32) | Chemotherapy group (n = 32) | P value |
| Best tumor response | |||
| Complete response | 0 (0) | 0 (0) | |
| Partial response | 10 (31.3) | 7 (20.6) | > 0.05 |
| Stable disease | 19 (59.4) | 18 (52.9) | > 0.05 |
| Progressive disease | 3 (9.4) | 9 (26.5) | > 0.05 |
| Objective response rate | 10 (31.3) | 7 (20.6) | > 0.05 |
| Disease control rate | 29 (90.6) | 25 (73.5) | > 0.05 |
| Median OS, months (95%CI) | 18.8 ± 2.6 (16.2-21.4) | 10.3 ± 2.3 (8-12.6) | < 0.05 |
| Median PFS, months (95%CI) | 9.6 ± 3.1 (6.5-12.7) | 5.4 ± 2.2 (3.3-7.7) | < 0.05 |
- Citation: Zhou SQ, Wan P, Zhang S, Ren Y, Li HT, Ke QH. Programmed cell death 1 inhibitor sintilimab plus S-1 and gemcitabine for liver metastatic pancreatic ductal adenocarcinoma. World J Clin Oncol 2025; 16(2): 98079
- URL: https://www.wjgnet.com/2218-4333/full/v16/i2/98079.htm
- DOI: https://dx.doi.org/10.5306/wjco.v16.i2.98079